Doctors of Meenakshi Mission Hospital has successfully used monoclonal antibody therapy to treat Anti-Glomerular Basement Membrane disease, helping a patient recover kidney function and come off ...

As the U.S. grapples with the lasting effects of the Covid-19 pandemic, it is important to highlight the ongoing challenges faced by the 7 million immunocompromised Americans. For them, the battle ...

From 31 centers, 166 patients were entered. Of this intent-to-treat group, 48% responded. With a median follow-up duration of 11.8 months, the projected median time to progression for responders is 13 ...

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking ...

Researchers in Switzerland have conducted the first systematic study that demonstrated that even small variations in a person’s genome can disrupt the therapeutic effects of monoclonal antibodies. “We ...

The expanded authorization was based on data from the phase 2/3 BLAZE-1 trial. The Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab plus ...

Monoclonal antibodies are among the most widely used biologic medicines, with applications ranging from cancer treatment to autoimmune disease therapy. However, during manufacturing, storage, or ...

Lecanemab, sold under the name Leqembi, is a monoclonal antibody therapy for Alzheimer's disease that clears toxic amyloid plaques and delays cognitive decline. Researchers from VIB and KU Leuven have ...

Crohn's disease and ulcerative colitis are complex diseases that have required the use of multiple modalities to aid in treatment. With an increasing understanding of the underlying pathogenetic ...

Because the antibodies are so selective for beta cells, the treatment appears to be safe for long-term use with few side effects, the team says. At this stage, the study has only been conducted in ...